Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BEAMNASDAQ:IBRXNASDAQ:IMNMNASDAQ:MLTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBEAMBeam Therapeutics$22.21+0.1%$26.65$20.84▼$35.25$2.22B1.911.28 million shs2.37 million shsIBRXImmunityBio$3.14-6.5%$3.13$2.28▼$10.53$2.68B0.825.58 million shs8.80 million shsIMNMImmunome$6.99-4.0%$9.50$6.90▼$24.87$607.79M1.93854,933 shs1.06 million shsMLTXMoonLake Immunotherapeutics$39.86+0.1%$42.17$36.52▼$58.26$2.55B1.31339,147 shs431,032 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBEAMBeam Therapeutics+0.09%-4.68%-20.37%-16.47%-34.60%IBRXImmunityBio-6.55%+15.87%+4.67%+12.95%-42.49%IMNMImmunome-3.98%-14.55%-27.04%-33.68%-72.61%MLTXMoonLake Immunotherapeutics+0.05%-0.65%-5.92%-28.01%-20.61%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBEAMBeam Therapeutics3.2745 of 5 stars4.51.00.00.03.22.50.6IBRXImmunityBio2.0341 of 5 stars3.51.00.00.02.51.70.6IMNMImmunome1.9642 of 5 stars3.51.00.00.02.72.50.0MLTXMoonLake Immunotherapeutics2.0853 of 5 stars3.51.00.00.03.12.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBEAMBeam Therapeutics 3.00Buy$49.45122.67% UpsideIBRXImmunityBio 3.00Buy$12.19288.14% UpsideIMNMImmunome 3.00Buy$25.50264.81% UpsideMLTXMoonLake Immunotherapeutics 3.00Buy$80.50101.96% UpsideCurrent Analyst Ratings BreakdownLatest IMNM, MLTX, IBRX, and BEAM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2025BEAMBeam TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$42.00 ➝ $42.003/20/2025IMNMImmunomeWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$33.00 ➝ $33.003/20/2025IMNMImmunomeStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$30.00 ➝ $30.003/20/2025IMNMImmunomeGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$35.00 ➝ $25.003/18/2025MLTXMoonLake ImmunotherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$67.003/13/2025IBRXImmunityBioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.003/13/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.003/12/2025BEAMBeam TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight3/11/2025IMNMImmunomeLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$20.003/10/2025BEAMBeam TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$34.003/10/2025BEAMBeam TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00(Data available from 3/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBEAMBeam Therapeutics$63.52M34.89N/AN/A$12.04 per share1.84IBRXImmunityBio$14.75M181.74N/AN/A($0.88) per share-3.57IMNMImmunome$9.04M67.23N/AN/A$2.77 per share2.52MLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$8.15 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBEAMBeam Therapeutics-$132.53M-$4.58N/AN/AN/A-41.07%-16.22%-10.94%5/6/2025 (Estimated)IBRXImmunityBio-$583.20M-$0.63N/AN/AN/A-8,016.83%N/A-110.02%5/8/2025 (Estimated)IMNMImmunome-$106.81M-$5.17N/AN/AN/A-3,014.59%-48.63%-41.62%5/13/2025 (Estimated)MLTXMoonLake Immunotherapeutics-$36.01M-$1.89N/AN/AN/AN/A-15.54%-15.09%5/6/2025 (Estimated)Latest IMNM, MLTX, IBRX, and BEAM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/19/2025Q4 2024IMNMImmunome-$0.68-$0.84-$0.16-$1.28$3.07 million$2.74 million3/3/2025Q4 2024IBRXImmunityBio-$0.26-$0.15+$0.11-$0.09$8.74 million$7.55 million2/26/2025Q4 2024MLTXMoonLake Immunotherapeutics-$0.63-$0.72-$0.09-$0.72N/AN/A2/25/2025Q4 2024BEAMBeam Therapeutics-$1.25-$1.09+$0.16-$1.09$16.47 million$30.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBEAMBeam Therapeutics$0.904.05%N/AN/A N/AIBRXImmunityBioN/AN/AN/AN/AN/AIMNMImmunomeN/AN/AN/AN/AN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBEAMBeam TherapeuticsN/A5.695.69IBRXImmunityBioN/A2.682.64IMNMImmunomeN/A6.176.17MLTXMoonLake ImmunotherapeuticsN/A25.5125.51Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBEAMBeam Therapeutics99.68%IBRXImmunityBio8.58%IMNMImmunome44.58%MLTXMoonLake Immunotherapeutics93.85%Insider OwnershipCompanyInsider OwnershipBEAMBeam Therapeutics4.20%IBRXImmunityBio83.40%IMNMImmunome8.60%MLTXMoonLake Immunotherapeutics12.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBEAMBeam Therapeutics51099.79 million79.33 millionOptionableIBRXImmunityBio590853.44 million115.67 millionOptionableIMNMImmunome4086.95 million72.92 millionOptionableMLTXMoonLake Immunotherapeutics264.01 million56.22 millionOptionableIMNM, MLTX, IBRX, and BEAM HeadlinesRecent News About These CompaniesBIT Capital GmbH Makes New $1.12 Million Investment in MoonLake Immunotherapeutics (NASDAQ:MLTX)March 28 at 6:32 AM | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Rating of "Buy" from AnalystsMarch 28 at 2:08 AM | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Up 2.9% - Still a Buy?March 19, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Now Covered by Royal Bank of CanadaMarch 19, 2025 | marketbeat.comRBC Capital Initiates Coverage of MoonLake Immunotherapeutics (MLTX) with Outperform RecommendationMarch 18, 2025 | msn.comMoonLake Immunotherapeutics initiated with an Outperform at RBC CapitalMarch 18, 2025 | markets.businessinsider.comRBC Capital Initiates a Buy Rating on MoonLake Immunotherapeutics (MLTX)March 18, 2025 | markets.businessinsider.comMoonLake Immunotherapeutics Advances Clinical Trials in 2024March 15, 2025 | tipranks.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Sold by Victory Capital Management Inc.March 14, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Hits New 52-Week Low - What's Next?March 11, 2025 | marketbeat.comCandriam S.C.A. Sells 11,524 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)March 8, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Given Consensus Recommendation of "Buy" by BrokeragesMarch 3, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for MLTX Q1 Earnings?March 3, 2025 | marketbeat.comWhat is Leerink Partnrs' Estimate for MLTX Q1 Earnings?March 3, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Position Decreased by Y Intercept Hong Kong LtdMarch 2, 2025 | marketbeat.comBrokers Offer Predictions for MLTX Q2 EarningsMarch 1, 2025 | marketbeat.comWedbush Has Negative Forecast for MLTX Q1 EarningsMarch 1, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target Cut to $73.00 by Analysts at The Goldman Sachs GroupFebruary 28, 2025 | marketbeat.comMoonLake Immunotherapeutics' (MLTX) "Buy" Rating Reiterated at HC WainwrightFebruary 28, 2025 | marketbeat.comNeedham & Company LLC Increases MoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target to $66.00February 28, 2025 | marketbeat.comMoonLake Immunotherapeutics: Buy Rating Backed by Promising SLK Data and Strong Financial PositionFebruary 27, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMNM, MLTX, IBRX, and BEAM Company DescriptionsBeam Therapeutics NASDAQ:BEAM$22.21 +0.02 (+0.09%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$22.20 -0.01 (-0.05%) As of 03/28/2025 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.ImmunityBio NASDAQ:IBRX$3.14 -0.22 (-6.55%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$3.04 -0.11 (-3.34%) As of 03/28/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.Immunome NASDAQ:IMNM$6.99 -0.29 (-3.98%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$7.08 +0.09 (+1.22%) As of 03/28/2025 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.MoonLake Immunotherapeutics NASDAQ:MLTX$39.86 +0.02 (+0.05%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$39.90 +0.04 (+0.09%) As of 03/28/2025 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas JPMorgan: The 'NVIDIA of Banking' Poised for More Gains? Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback Joby Aviation Stock: Analyst Confidence and Smart Money Align Ibotta Stock: Why the Buyback Looks Like a Bullish Bet Archer Aviation Stock Sees Surge in Institutional Buys How Can Tomahawk 6 Contribute to Broadcom's AI Growth Story? Microsoft’s Big Malaysia Bet Could Pay Off for Investors Intuitive Machines Gains After Earnings Beat, NASA Missions Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
